John V Heymach Selected Research

vandetanib (ZD6474)

4/2016	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
3/2016	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
7/2015	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
6/2011	The BATTLE trial: personalizing therapy for lung cancer.
7/2010	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
5/2010	A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
1/2010	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
5/2009	Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
5/2009	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
11/2008	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John V Heymach Research Topics

Disease

176	Neoplasms (Cancer) 11/2022 - 09/2004
126	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 03/2006
67	Lung Neoplasms (Lung Cancer) 08/2022 - 06/2004
25	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2012
21	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 06/2004
20	Adenocarcinoma of Lung 05/2022 - 10/2006
11	Hypoxia (Hypoxemia) 01/2021 - 02/2007
11	Disease Progression 01/2021 - 05/2009
11	Squamous Cell Carcinoma of Head and Neck 01/2021 - 06/2010
9	Carcinogenesis 01/2021 - 01/2012
7	Adenocarcinoma 03/2021 - 07/2015
6	Melanoma (Melanoma, Malignant) 01/2022 - 04/2010
6	Breast Neoplasms (Breast Cancer) 12/2018 - 12/2008
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 10/2017
5	Brain Neoplasms (Brain Tumor) 01/2021 - 06/2008
5	Exanthema (Rash) 01/2020 - 07/2010
4	Malignant Mesothelioma 10/2020 - 06/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 04/2011
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 05/2009
3	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 07/2011
3	COVID-19 11/2021 - 01/2021
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 09/2004
3	Carcinoma (Carcinomatosis) 01/2020 - 10/2006
3	Ovarian Neoplasms (Ovarian Cancer) 04/2017 - 01/2007
3	Leukemia 01/2017 - 05/2012
3	Colorectal Neoplasms (Colorectal Cancer) 01/2013 - 01/2010
2	Sepsis (Septicemia) 01/2022 - 02/2018
2	Lymphoma (Lymphomas) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

32	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2007
28	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2008
23	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 05/2005
21	ErbB Receptors (EGF Receptor)IBA 12/2021 - 07/2006
18	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2016
16	Pharmaceutical PreparationsIBA 01/2021 - 01/2005
15	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2006
15	vandetanib (ZD6474)IBA 04/2016 - 07/2006
13	Tyrosine Kinase InhibitorsIBA 01/2021 - 05/2007
12	CytokinesIBA 01/2022 - 01/2010
12	Phosphotransferases (Kinase)IBA 01/2021 - 12/2007
11	LigandsIBA 01/2021 - 09/2012
11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2016
11	Angiogenesis InhibitorsIBA 10/2019 - 09/2004
10	Bevacizumab (Avastin)FDA Link 01/2021 - 03/2006
9	Biological ProductsIBA 01/2020 - 01/2005
9	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2012
9	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2007
8	PlatinumIBA 01/2022 - 08/2011
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 02/2007
8	RNA (Ribonucleic Acid)IBA 10/2021 - 02/2016
8	Circulating Tumor DNAIBA 01/2021 - 03/2016
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2012 - 09/2004
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2022 - 10/2017
7	Gefitinib (Iressa)FDA Link 05/2009 - 07/2006
6	Messenger RNA (mRNA)IBA 01/2020 - 05/2008
6	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 11/2008
5	HM781-36BIBA 11/2022 - 10/2019
5	AntigensIBA 01/2022 - 05/2014
5	Peptides (Polypeptides)IBA 01/2022 - 03/2014
5	B7-H1 AntigenIBA 01/2021 - 02/2016
5	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2007
5	Carboplatin (JM8)FDA LinkGeneric 12/2013 - 11/2008
4	AntibodiesIBA 01/2022 - 04/2011
4	NucleotidesIBA 01/2022 - 08/2013
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 11/2013
4	Sorafenib (BAY 43-9006)FDA Link 10/2016 - 06/2011
4	Cetuximab (Erbitux)FDA Link 12/2013 - 07/2006
3	NivolumabIBA 11/2022 - 01/2018
3	IpilimumabIBA 11/2022 - 12/2019
3	osimertinibIBA 01/2022 - 12/2018
3	InterleukinsIBA 01/2022 - 03/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 09/2012
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2012
3	Transcription Factors (Transcription Factor)IBA 01/2021 - 08/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2021 - 03/2010
3	pembrolizumabIBA 10/2020 - 01/2020
3	Small Interfering RNA (siRNA)IBA 01/2020 - 04/2017
3	ChemokinesIBA 01/2020 - 07/2011
3	Protons (Proton)IBA 01/2020 - 01/2017
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 08/2013
3	cediranib (AZD2171)IBA 10/2019 - 08/2007
3	MicroRNAs (MicroRNA)IBA 01/2019 - 08/2014
3	EnzymesIBA 01/2019 - 01/2010
3	pazopanib FDA Link 01/2018 - 03/2010
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 09/2008
3	Sunitinib (Sutent)FDA Link 11/2012 - 05/2007
3	afliberceptIBA 11/2011 - 12/2008
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2011 - 01/2005
2	trametinibIBA 01/2022 - 01/2020
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2015
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2017
2	durvalumabIBA 01/2022 - 01/2022
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2021 - 06/2010

Therapy/Procedure

85	Therapeutics 08/2022 - 01/2005
37	Drug Therapy (Chemotherapy) 11/2022 - 06/2004
37	Radiotherapy 01/2022 - 04/2011
22	Immunotherapy 08/2022 - 01/2016
6	Neoadjuvant Therapy 01/2022 - 01/2018
4	Aftercare (After-Treatment) 01/2021 - 09/2016
3	Chemoradiotherapy 01/2022 - 01/2013
3	Proton Therapy 01/2021 - 01/2018